| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ssaA2 |
| Uniprot No | Q99RX4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-267aa |
| 氨基酸序列 | SEQDNYGYNPNDPTSYSYTYTIDAQGNYHYTWKGNWHPSQLNQDNGYYSYYYYNGYNNYNNYNNGYSYNNYSRYNNYSNNNQSYNYNNYNSYNTNSYRTGGLGASYSTSSNNVQVTTTMAPSSNGRSISSGYTSGRNLYTSGQCTYYVFDRVGGKIGSTWGNASNWANAAARAGYTVNNTPKAGAIMQTTQGAYGHVAYVESVNSNGSVRVSEMNYGYGPGVVTSRTISASQAAGYNFIH |
| 预测分子量 | 42.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ssaA2重组蛋白的3篇参考文献的简要概括(注：文献信息为示例性模拟，实际引用时请核实真实来源)：
1. **"Cloning and Immunogenicity Analysis of the SsaA2 Recombinant Protein from Salmonella Typhimurium"**
*作者：Smith J, et al.*
摘要：本研究成功克隆并表达了沙门氏菌毒力相关基因ssaA2的重组蛋白，证实其可在体外诱导巨噬细胞炎性反应，并作为潜在疫苗候选抗原在小鼠模型中引发特异性抗体应答。
2. **"SsaA2 Recombinant Protein as a Diagnostic Marker for Salmonella Infection"**
*作者：Wang L, et al.*
摘要：通过原核系统表达纯化ssaA2重组蛋白，发现其与沙门氏菌感染患者血清抗体具有高亲和力，提示其作为血清学诊断靶标的潜在应用价值。
3. **"Functional Characterization of SsaA2 in Bacterial Virulence via Recombinant Protein Complementation"**
*作者：García R, et al.*
摘要：利用重组ssaA2蛋白回补基因缺失株，证实该蛋白在沙门氏菌Ⅲ型分泌系统(T3SS)中调控效应蛋白转运的功能，揭示了其在宿主细胞内生存的关键作用。
(注：若需真实文献，建议在PubMed等平台以关键词“SsaA2 recombinant”、“Salmonella SsaA2”进一步检索。)
The SsaA2 recombinant protein is derived from the SsaA2 gene, a component of the *Salmonella enterica* serovar Typhimurium pathogenicity island 2 (SPI-2). SPI-2 is a critical virulence factor enabling intracellular survival and replication of *Salmonella* within host cells, particularly within macrophages. The SsaA2 protein is part of the SPI-2-encoded type III secretion system (T3SS), a molecular syringe-like apparatus that translocates effector proteins into host cells to subvert immune responses and establish a replicative niche. SsaA2 specifically functions as a structural or chaperone protein, facilitating the assembly or stabilization of the T3SS apparatus or its secreted effectors.
Recombinant SsaA2 is produced through genetic engineering, typically by cloning the *ssaA2* gene into expression vectors (e.g., *E. coli* systems) for overexpression. The protein is purified using affinity chromatography, often tagged with histidine or other epitopes for ease of isolation. Its recombinant form enables detailed biochemical and immunological studies, including structural analysis (e.g., X-ray crystallography or cryo-EM) to elucidate its role in SPI-2-mediated pathogenesis.
Research on SsaA2 recombinant protein focuses on understanding *Salmonella* virulence mechanisms, host-pathogen interactions, and potential therapeutic applications. It serves as a target for vaccine development, as SPI-2 components are immunogenic and critical for bacterial survival. Studies have explored SsaA2 as a subunit vaccine candidate, demonstrating its ability to elicit protective immune responses in animal models. Additionally, it aids in diagnostic tool development for detecting *Salmonella* infections. Its recombinant production bypasses the need for pathogenic *Salmonella* cultures, enhancing safety and scalability for research and clinical use. Overall, SsaA2 recombinant protein is a valuable tool in combating salmonellosis and advancing antimicrobial strategies.
×
